Compare VYGR & NREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | NREF |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0M | 244.2M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | NREF |
|---|---|---|
| Price | $3.76 | $13.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $21.00 | $14.50 |
| AVG Volume (30 Days) | ★ 837.1K | 48.1K |
| Earning Date | 03-09-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 15.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $54.19 | $24.65 |
| Revenue Next Year | $20.22 | N/A |
| P/E Ratio | ★ N/A | $4.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $12.14 |
| 52 Week High | $5.55 | $16.80 |
| Indicator | VYGR | NREF |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 29.18 |
| Support Level | $3.60 | $12.36 |
| Resistance Level | $4.43 | $15.25 |
| Average True Range (ATR) | 0.33 | 0.44 |
| MACD | -0.03 | -0.18 |
| Stochastic Oscillator | 4.37 | 3.97 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.